Compare BQ & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BQ | PRFX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 2.6M |
| IPO Year | 2020 | 2020 |
| Metric | BQ | PRFX |
|---|---|---|
| Price | $0.93 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 4.4M |
| Earning Date | 01-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $0.58 |
| 52 Week High | $72.74 | $5.39 |
| Indicator | BQ | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 47.68 |
| Support Level | $0.69 | $1.29 |
| Resistance Level | $0.96 | $2.89 |
| Average True Range (ATR) | 0.17 | 0.41 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 30.81 | 11.11 |
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.